Drug Trial Radar · NCT02847442
Efficacy and Safety of Opicapone in Clinical Practice
Last checked: Nov 19, 2026Latest source record: Oct 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
518
Actual
Start
Nov 23, 2016
Primary completion
Jul 4, 2018
Study completion Jul 4, 2018
Sponsor
- Lead sponsor
- Bial - Portela C S.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the change in subject's condition according to the Investigator's Global Assessment of Change after three months of treatment with 50 mg opicapone once daily in a heterogeneous patient population reflecting daily clinical practice.
Conditions
- Parkinson's Disease With Wearing-off Motor Fluctuations
Interventions
BIA 9-1067Drug
Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
levodopa/dopa decarboxylase inhibitorDrug
OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator's Global Assessment of ChangeTime frame: Through study completion, an average of three months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Carl Gustav Carus at the TU Dresden, Neurological University Clinic
Dresden, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.